190 related articles for article (PubMed ID: 19555178)
1. QSAR of aminopyrido[2,3-d]pyrimidin-7-yl derivatives: anticancer drug design by computed descriptors.
Nandi S; Bagchi MC
J Enzyme Inhib Med Chem; 2009 Aug; 24(4):937-48. PubMed ID: 19555178
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of selected phenolic compounds: QSAR studies using ridge regression and neural networks.
Nandi S; Vracko M; Bagchi MC
Chem Biol Drug Des; 2007 Nov; 70(5):424-36. PubMed ID: 17949360
[TBL] [Abstract][Full Text] [Related]
3. Activity prediction of some nontested anticancer compounds using GA-based PLS regression models.
Nandi S; Bagchi MC
Chem Biol Drug Des; 2011 Oct; 78(4):587-95. PubMed ID: 21752199
[TBL] [Abstract][Full Text] [Related]
4. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
5. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
6. QSAR modeling of anti-invasive activity of organic compounds using structural descriptors.
Katritzky AR; Kuanar M; Dobchev DA; Vanhoecke BW; Karelson M; Parmar VS; Stevens CV; Bracke ME
Bioorg Med Chem; 2006 Oct; 14(20):6933-9. PubMed ID: 16908166
[TBL] [Abstract][Full Text] [Related]
7. Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors.
Marrero-Ponce Y
J Chem Inf Comput Sci; 2004; 44(6):2010-26. PubMed ID: 15554670
[TBL] [Abstract][Full Text] [Related]
8. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
9. Molecule kernels: a descriptor- and alignment-free quantitative structure-activity relationship approach.
Mohr JA; Jain BJ; Obermayer K
J Chem Inf Model; 2008 Sep; 48(9):1868-81. PubMed ID: 18767832
[TBL] [Abstract][Full Text] [Related]
10. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors.
Cormanich RA; Goodarzi M; Freitas MP
Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
12. QSAR analysis of 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines with anticancer activity.
Atanasova M; Ilieva S; Galabov B
Eur J Med Chem; 2007 Sep; 42(9):1184-92. PubMed ID: 17408810
[TBL] [Abstract][Full Text] [Related]
13. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
14. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
15. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
Karkola S; Lilienkampf A; Wähälä K
ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
[TBL] [Abstract][Full Text] [Related]
16. Design and QSAR study of analogs of gamma-tocotrienol with enhanced antiproliferative activity against human breast cancer cells.
Nikolic K; Agababa D
J Mol Graph Model; 2009 Apr; 27(7):777-83. PubMed ID: 19117779
[TBL] [Abstract][Full Text] [Related]
17. Phenylpropiophenone derivatives as potential anticancer agents: synthesis, biological evaluation and quantitative structure-activity relationship study.
Ivković BM; Nikolic K; Ilić BB; Žižak ŽS; Novaković RB; Čudina OA; Vladimirov SM
Eur J Med Chem; 2013 May; 63():239-55. PubMed ID: 23501110
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolodiazine and triazine analogs.
El-Shafei A; Fadda AA; Khalil AM; Ameen TA; Badria FA
Bioorg Med Chem; 2009 Jul; 17(14):5096-105. PubMed ID: 19527933
[TBL] [Abstract][Full Text] [Related]
19. QSAR modeling using chirality descriptors derived from molecular topology.
Golbraikh A; Tropsha A
J Chem Inf Comput Sci; 2003; 43(1):144-54. PubMed ID: 12546547
[TBL] [Abstract][Full Text] [Related]
20. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
